Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The EGFR mutation-response or mutation-PFS correlation for afatinib in NSCLC treatment was computationally profiled, promoting specialized and innovative drug design.